Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 34.50p 159,250 08:00:00
Bid Price Offer Price High Price Low Price Open Price
33.00p 36.00p 34.50p 34.50p 34.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 25.40 -10.88 -10.56 24.2

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-07-20 16:07:1334.5010,0003,450.00O
2018-07-20 15:17:0435.802,220794.76O
2018-07-20 14:49:0334.131,587541.64O
2018-07-20 14:43:0835.5030,00010,650.00O
2018-07-20 14:40:1834.133,1881,088.06O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

DateSubject
21/7/2018
09:20
Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 34.50p.
Summit Corporation has a 4 week average price of 32p and a 12 week average price of 32p.
The 1 year high share price is 265p while the 1 year low share price is currently 32p.
There are currently 70,260,991 shares in issue and the average daily traded volume is 223,224 shares. The market capitalisation of Summit Corporation is £24,240,041.90.
01/7/2018
13:40
wildbunch: They are going to burn their cash pile and more on their programs. So-it is dependent on one or other of the drugs working and getting it to market profitably-who know what the competition will be in 3 to 5 years time. They have taken ages to get C Diff to phase 3. Personally I am fed up with the CEO's 'excitement' and putting all delays down to 'that's drug development for you' and getting massive cash bonuses-which do not go into share purchases-for achieving unspecified corporate objectives-and a Chair of the remuneration c'tee who never attends AGM to be questioned.. I have sold a portion of my shares-so my average is much higher-because, for me, the credibility of the top management is shot to pieces. I hope that there is some residue of value in the new potential DMD drugs that Oxford Uni are working on. I do not see that before this announcement that there was much implied value in the non DMD programs and this has been borne out by the drop in share price. Maybe it is over done-maybe not. I imagine that morale must be low-big redundancies on the cards. Is having operations in the US and UK viable? Do we really need a CEO and COO with a reduced size operation. Fund raising will have to be via grants-otherwise the dilution will be massive-will the management have the credibility to get grants after this failure? Sorry to sound negative. This is not sour grapes. Trying to be realistic. Obviously those entering now can a adopt 'a clean sheet of paper' approach. Good luck to them-and beware. That's all.
29/6/2018
16:20
chrisatrdg: A challenge for the weekend. A company that has a new antibiotic going into phase 3 (Good phase 2) & a platform to fight super bugs currently at early stage development & financed.What price per share would you put on that company - I would suggest £1 any further thoughts. Edit : I note that the NASDAQ share price is starting to recover.
28/6/2018
19:00
cantrememberthis2: Kirk unlike IMM and FARN we have no chatter or pump and dump crew. So highly unusual that the share price Take No Account of £10m Discuva acquisition or indeed the IPR. Barely factors in £25m cash in the bank with immediate reduction in spend nor the promising pipeline(s). Also a Phase 3 Trial in 6 months.... Whereas IMM and Farn bounced massively to then come down. Holding 62k shares... Its peeps like me who have absorbed the sellers.
27/6/2018
14:46
chrisatrdg: I feel the same way waterloo01 takes me back to the meeting we all had at which Summit had to raise more capital & the share price halved but this is worse.This is Antisoma all over again we were warned.I just cannot understand why at 24 wks all looked so good just need to match it at 48 wks & here we are pulling the plug.Something wrong ?
08/6/2018
09:18
wildbunch: HM. Don't lets carried away by the comparison. Just a £125k swing overnight makes one think about risk/reward! I also chatted with execs after the AGM. Of course a £200m offer would be resisted. However, Sarepta has both cash and paper and potentially a strategic imperative to own Summits DMD portfolio sooner rather than later. There are a number of price inflection points looming. Should we get the results the execs are clearly anticipating then the share price must rise-then more so each time more news-approach to regulators for fast track-approval granted-launch-sales numbers etc. It would make sense for Sarepta to come in as soon as they think they could strike a deal-this could be in the £500m to £1bn range-personally I would not want that if the July results are good.
21/5/2018
13:27
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
01/5/2018
17:29
luminoso: Strengthening dollar has offset recent fall on nasdaq and prevented it being translated to AIM in the form of a few pence off our price. The inertia of the SUMM price works both ways and will only really react to quite dramatic moves in SMMT over on nasdaq, I guess.
27/3/2018
08:28
football: Suppose I'm like most here clicked on the newsfeed and you see another big placing and think FFS not again! But then you look at the price of the placing and it's only 4-5p below the bid price which isn't that bad at all. As Hyper Al says it looks like someone wanted in pretty quick and maybe before any drug results hit the market, this placing would have taken a few days so the price probably was about £1.80 when agreed so they probably paid the full price to get in quick rather than spreading it over a couple weeks and maybe forcing the price up higher and costing them more or any positive test results which would of made the share price a lot higher. gla Summit Therapeutics launches placing to raise £15mln to advance its treatment for Duchenne Muscular Dystrophy 07:40 27 Mar 2018 The company said it expects to use the placing’s net proceeds to accelerate preparatory activities for a placebo-controlled clinical trial for DMD treatment ezutromid Read more http://www.proactiveinvestors.co.uk/companies/news/193847/summit-therapeutics-launches-placing-to-raise-15mln-to-advance-its-treatment-for-duchenne-muscular-dystrophy-193847.html
09/2/2018
14:21
hugus maximus: filmster .... well done, I should have sold some but was waiting for a NASDAQ share price hike that didn't materialise. Share price drop has deepened over past few days as the dollar / pound rate moved against us .... uk shares are dollar led ... aside from overall 4% drop in Biotech this week as a result of general share drift. There is nothing to suggest any negative news about the progress of either DMD P2 or C Diff at Summit.
14/12/2017
22:24
stephen2010: ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
Summit Corp share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180721 10:07:07